Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 10/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035863 | 0.96 | PPARD (0.41) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6035797 | 0.93 | PPARD (0.42) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6036305 | 0.90 | PPARG (0.39) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6035923 | 0.88 | SMN1; SMN2 (0.36) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6034680 | 0.88 | LTB4R (0.44) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6035912 | 0.88 | PPARD (0.44) | PPARDKDM4ELMNASMN1; SMN2PPARG | |
| SCHEMBL6035760 | 0.87 | SMN1; SMN2 (0.43) | PPARDKDM4ELMNASMN1; SMN2PPARG | |
| SCHEMBL6036248 | 0.86 | PPARD (0.40) | PPARDPTGDR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6036155 | 0.86 | HCRTR1 (0.36) | PTGDR2KDM4ELMNASMN1; SMN2PPARG | |
| SCHEMBL6036245 | 0.85 | PPARD (0.42) | PPARDKDM4ELMNASMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARD 2488/4885PTGDR2 4688/4885KDM4E 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.